Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 2/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.51 |
| ▸ | F10 | P00742 | 12/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4681207 | 0.83 | F10 (0.67) | F10 | |
| SCHEMBL5914269 | 0.80 | F10 (0.73) | F10 | |
| SCHEMBL5768089 | 0.76 | F10 (0.69) | F10 | |
| SCHEMBL6988052 | 0.73 | F10 (0.58) | F10 | |
| SCHEMBL6988797 | 0.73 | F10 (0.44) | F10 | |
| SCHEMBL6983760 | 0.72 | F10 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7139450 | 0.71 | FPR2 (0.55) | F10 | |
| SCHEMBL28703156 | 0.71 | F10 (0.42) | F10 | |
| SCHEMBL6987862 | 0.70 | F10 (0.54) | F10 | |
| SCHEMBL6989692 | 0.70 | F10 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337251-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-08-27 | — | — | EP | claimed |
| WO-2002102380-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-12-27 | — | — | WO | claimed |